Digital health innovations are helping achieve a long-sought-after healthcare industry objective: cutting healthcare costs while improving patient outcomes simultaneously—an outcome that is especially important given the impact of the COVID-19 pandemic. By decisively selecting which value pools and strategies to prioritize, healthcare investors and companies can effectively thrive in the fast-growing digital health space and improve healthcare for patients worldwide.
Researchers at the University of Queensland and WEHI have identified a new generation anti-cancer drug that could be repurposed for aggressive childhood brain tumour, medulloblastoma. The international collaboration spent five years mapping the genetics of this common and fatal brain cancer for children. The existing drug has been approved for other diseases or cancers but never tested in paediatric brain tumours. Ixabepilone which is used to treat breast cancer, was found to block tumour growth and significantly extend survival rates in preclinical models. | https://www.uq.edu.au/news/node/129501
Australia's Monash University have received a $2.97 million Medical Research Future Fund grant to commence a new DNA screening study that will identify cancer risk in young adults. The study will develop a low-cost test offered to 10,000 young Aussies with the aim to drastically improve access to preventative genetic testing. Associate Professor Paul Lacaze will work with a team of internationally recognised leaders to develop this tool and accelerate implementation into the healthcare system. | shorturl.at/kxAC5